Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer
NCT05052723Phase 2Completed
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, pembrolizumab in pancreatic ductal adenocarcinoma (PDAC). Started Jan 2022; status: completed.
02
Drugs
cabozantinibpembrolizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05052723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052723.